Skin & hair

The Point Where Patches Call for a Pill

Save

Alopecia areata usually starts with topical steroids, steroid injections into the patches, or both. A systemic pill enters the conversation when those stop working, when hair loss spreads to eyebrows or eyelashes, or when patches keep enlarging for months — not because a single missed regrowth cycle means treatment failed. Here is how dermatologists weigh that decision, and what the pill options actually involve once you're there.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What Signals That Topical Treatment Has Stopped Working?

Alopecia areata escalates toward a systemic pill when the pattern, not a single bad week, points that way: patches keep enlarging or new ones appear despite months of topical or injected steroids, hair loss covers a large share of the scalp, or the disease has moved beyond the scalp into eyebrows, eyelashes, or beard hair. Any one of these is reason enough to raise the conversation with a dermatologist.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, and its course is genuinely unpredictable — some patches regrow without any treatment at all, while others sit unchanged through months of topical therapy 1. That unpredictability is exactly why dermatologists don't chase a single patch with escalating creams indefinitely. If topical measures haven't changed the trajectory after a reasonable trial — typically several months — that's the signal to talk about what comes next, rather than a reason to assume nothing will ever work.

The Steps Usually Tried Before a Pill

Most alopecia areata treatment starts local: a potent topical corticosteroid applied directly to the patches, and for many people, steroid injections for alopecia areata — small injections of corticosteroid into the scalp at the edge of each bald patch, repeated every several weeks. Topical immunotherapy, which deliberately provokes a mild allergic contact reaction to redirect the immune response, is another option tried before anything systemic.

These local treatments act directly on the follicles that are affected and carry none of the whole-body exposure a pill does, which is why they come first even when the patches are frustratingly slow to respond. The injections sting for a few seconds and are typically done in-office, repeated over several visits; for scalp patches under a few centimeters, many dermatologists will try this route for months before discussing a pill at all. The calculus changes when the area involved is too large for injections to cover practically, or when new patches keep opening faster than existing ones close.

What a JAK Inhibitor Pill Actually Does

JAK inhibitor pills for alopecia areata work by blocking a signaling pathway (JAK1 and JAK2) that immune cells use to attack hair follicles, rather than suppressing the immune system broadly. Baricitinib, taken as a daily pill, became the first systemic drug specifically approved for severe alopecia areata after two phase 3 trials showed it regrew hair to near-normal scalp coverage in a meaningful share of adults with severe disease, measured at week 36 2.

Regrowth on a JAK inhibitor is measured in months, not weeks. In the trials that led to approval, people with severe alopecia areata took the pill daily for 36 weeks before the primary result was assessed, and hair regrowth continued to improve for some past that point. That timeline matters for expectations: this isn't a treatment where an uneven response at eight weeks means it has failed. Baricitinib isn't the only oral JAK inhibitor studied for alopecia areata — ritlecitinib is separately approved — but the trial evidence behind the drug class is what makes the case for trying one at all.

How Is Alopecia Areata Severity Measured?

Dermatologists use a tool called the SALT score — the Severity of Alopecia Tool — which scores scalp hair loss as a percentage, from 0 (no loss) to 100 (complete loss), by dividing the scalp into four regions and estimating the bald fraction of each. It is the measurement dermatologists and trial researchers use to describe how extensive a case is and to track whether treatment is working, rather than relying on a subjective before-and-after impression.

In the pivotal baricitinib trials, adults with severe alopecia areata who responded to treatment reached a SALT score of 20 or less — meaning 80% or more of scalp hair had regrown — by week 36 2. A SALT score isn't something you're expected to calculate yourself; a dermatologist estimates it at each visit. But knowing the scale helps make sense of language like "severe" or "extensive" alopecia areata when it comes up in a treatment conversation, and it's often the kind of number an insurer wants documented before approving a systemic pill.

Eyebrows, Eyelashes, and Beard Hair

Alopecia beyond the scalp — in the eyebrows, eyelashes, or beard — changes the calculus even when scalp involvement itself is limited. Eyebrow and eyelash loss removes a layer of physical protection, since eyelashes keep debris out of the eyes, and both are far more visible day to day than a covered scalp patch, which is why dermatologists weigh involvement beyond the scalp as its own reason to discuss systemic treatment sooner, rather than waiting for scalp involvement to reach a particular threshold first.

Facial and body hair involvement also tends to track with a more active disease process rather than a single isolated patch, which is part of why it shifts the conversation. There's no separate approval pathway for eyebrow-only or eyelash-only alopecia areata — the same JAK inhibitor pills studied for scalp disease are the ones used here — but the decision to start one often comes earlier when facial hair is involved, simply because the functional and visible impact is higher for the same amount of hair loss.

Approaching Total or Universal Hair Loss

Alopecia totalis — complete loss of scalp hair — and alopecia universalis, which extends to all body hair, represent the far end of the alopecia areata spectrum. Reaching this point doesn't foreclose treatment, but it does tend to accelerate the conversation about a systemic pill, because at that stage there's no longer a smaller patch to treat locally with injections — the disease has outpaced what a needle and a tube of cream can practically cover.

At this stage, a systemic pill is often the only practical option left, since injections work patch by patch and can't reasonably cover an entire scalp or body. That's a logistical reality more than a medical verdict on whether treatment can still help: the trials that led to baricitinib's approval were conducted specifically in adults with severe alopecia areata 2, a category that includes total and universal disease. Whether a particular case will respond is something only a dermatologist following that person over time can assess.

What Starting a Systemic Pill Involves

Starting a JAK inhibitor for alopecia areata isn't the same commitment as adding a tube of cream. Because these pills work by modulating the immune system rather than acting locally, dermatologists typically order baseline bloodwork before starting and monitor periodically afterward, and they will ask about infection history, since immune-modulating drugs affect the body's ability to fight some infections. None of this means the pill is unusually risky — it means it's treated with the oversight any systemic immune-modulating medication gets.

This isn't unique to alopecia areata. The same class of systemic options — JAK inhibitors alongside older immune-modulating drugs — is also how dermatologists escalate care for other autoimmune skin diseases once topical treatment stops being enough, including moderate-to-severe eczema 3. The shared logic is worth knowing: a systemic pill is a bigger step than a cream, but it's a well-established one, with monitoring built into how it's prescribed rather than left to chance.

Bringing This Up With a Dermatologist

The conversation about escalating alopecia areata treatment options goes better with specifics in hand: how long topical or injected treatment has been tried, how much of the scalp, and any eyebrows, eyelashes, or beard hair, is currently affected, and whether new patches have appeared recently or the situation has been stable. A dermatologist uses those details, plus a SALT score estimate, to decide whether a systemic pill is a reasonable next step or whether more time on local treatment makes sense first.

It's also worth asking directly what response would count as working and on what timeline, since JAK inhibitor results build over months rather than weeks. Insurance coverage for these pills often requires documentation of prior treatment and disease severity, so a dermatologist's office may need time to submit that before a prescription is approved — worth asking about early rather than assuming a same-day start.

Common questions

Many people see meaningful regrowth, but responses vary and aren't guaranteed for everyone — alopecia areata's course is unpredictable even with treatment. Trials of the pills used for severe disease showed substantial regrowth in a meaningful share of participants by around nine months, but some people respond partially and some don't respond at all. A dermatologist can discuss realistic expectations based on your specific pattern and history.

Results build slowly. In the trials that led to approval, the main outcome was measured after 36 weeks of daily treatment, and some people continued improving beyond that point. It's not unusual to see little visible change in the first couple of months — that isn't necessarily a sign the pill isn't working, and stopping early is a common reason a genuinely effective treatment gets abandoned too soon.

It's a brief, sharp sting at each injection point, similar to other small injections, rather than a lasting pain. Most people tolerate a course of injections across several patches in one visit, and the discomfort passes quickly. Numbing cream beforehand is an option worth asking about if needle anxiety is a bigger obstacle than the injections themselves.

Age matters for which options are appropriate — some JAK inhibitors approved for alopecia areata have authorization extending down into adolescence, while others are studied primarily in adults. A pediatric dermatologist weighs a child's age, extent of hair loss, and psychosocial impact differently than an adult case, and topical and injected options are typically exhausted first regardless of age.

Coverage usually requires documentation — a SALT score showing the extent of hair loss, and proof that topical or injected treatments were tried first and didn't sufficiently work. Prior authorization is common and can take days to weeks to process, so it's worth asking a dermatologist's office to start that paperwork as soon as a systemic pill is being seriously considered.

Alopecia areata can return after stopping systemic treatment, since these pills manage the immune activity driving hair loss rather than curing the underlying disease. Some people maintain regrowth for a period after stopping; others see patches recur within months. That's a conversation worth having with a dermatologist before starting, since it shapes whether the pill is a short course or a longer-term commitment.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to Get Alopecia Areata Checked Promptly

  • —Hair loss spreading rapidly enough to cover more than a small patch within a few weeks
  • —New involvement of eyebrows, eyelashes, or beard hair alongside scalp patches
  • —Signs of infection at an injection site, such as spreading redness, warmth, or pus
  • —Significant distress, social withdrawal, or anxiety connected to visible hair loss

This article explains how dermatologists generally approach escalating alopecia areata treatment. It is not a substitute for an evaluation by a dermatologist, who can assess your specific pattern of hair loss and recommend a course of treatment.

References

  1. 1.National Institute of Arthritis and Musculoskeletal and Skin Diseases (2024). Alopecia Areata. NIH / NIAMS. link ✓Definitional statement that alopecia areata is an autoimmune disease attacking hair follicles with an unpredictable course.
  2. 2.King B, Ohyama M, Kwon O, et al. (2022). Two Phase 3 Trials of Baricitinib for Alopecia Areata. New England Journal of Medicine. doi:10.1056/NEJMoa2110343BRAVE-AA1/AA2 trial results: oral baricitinib regrows hair to SALT ≤20 at week 36 in adults with severe alopecia areata, the basis for its approval and the timeline for expected response.
  3. 3.Sidbury R, Davis DM, Alikhan A, et al. (2024). Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology. PMID 37943240Parallel example that JAK inhibitors and other systemic immune-modulating drugs are also how dermatologists escalate care for other autoimmune skin diseases, such as moderate-to-severe eczema, once topical treatment is insufficient.

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library